Skip to main content
. 2022 Jan 12;45(2):127–136. doi: 10.1007/s40264-021-01125-4

Fig. 1.

Fig. 1

Comparison of adverse events (AEs) reported in patients receiving imiglucerase in Mexico before and after Asbroder approval. Infusion-associated reactions are product-related AEs occurring within 24 h of the infusion. IAR infusion-associated reactions